Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 4OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 45Neoplasms 27Uterine Cervical Neoplasms 24Prostatic Neoplasms 21Carcinoma, Non-Small-Cell Lung 20Colorectal Neoplasms 19Stomach Neoplasms 18Carcinoma, Hepatocellular 16Multiple Myeloma 14Ovarian Neoplasms 11Recurrence 10Pancreatic Neoplasms 10Esophageal Squamous Cell Carcinoma 10Esophageal Neoplasms 9Leukemia, Myeloid, Acute 8Endometrial Neoplasms 8Lymphoma 7Lung Neoplasms 7Brain Neoplasms 7Liver Neoplasms 6Leukemia 6Disease 6Carcinoma, Ovarian Epithelial 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Rectal Neoplasms 5Papillomavirus Infections 5Colonic Neoplasms 5Urinary Bladder Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4

Interventions

camrelizumab 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER_GOV × Esophageal Diseases × Clear all
NCT05624099 2023-10-19

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Fujian Cancer Hospital

Phase 2 Recruiting
75 enrolled
Gastrointestinal

Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡